✦ LIBER ✦

Is epidermal growth factor present in human blood? Interference with the radioreceptor assay for epidermal growth factor

✍ Scribed by D.F. Bowen-Pope; R. Ross

Book ID: 115756582
Publisher: Elsevier Science
Year: 1983
Tongue: English
Weight: 355 KB
Volume: 114
Category: Article
ISSN: 0006-291X
DOI: 10.1016/0006-291x(83)90666-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Human epidermal growth factor—on molecul

Human epidermal growth factor—on molecular forms present in urine and blood

✍ Ebba Nexø; Per E. Jørgensen; Marianne Rye Hansen 📂 Article 📅 1992 🏛 Elsevier Science 🌐 English ⚖ 555 KB

Endogenous ligands for the epidermal gro

Endogenous ligands for the epidermal growth factor receptor in human breast tumors do not interfere in an epidermal growth factor receptor radioligand binding assay

✍ Clemens B. M. Kienhuis; Paul G. Koenders; Helena Klominska; Theo J. Benraad 📂 Article 📅 1993 🏛 Springer US 🌐 English ⚖ 435 KB

The receptor for epidermal growth factor

The receptor for epidermal growth factor is present in human fetal kidney, liver and lung

✍ Ebba Nexø; Niels Kryger-Baggesen 📂 Article 📅 1989 🏛 Elsevier Science 🌐 English ⚖ 410 KB

The first epidermal growth factor domain

The first epidermal growth factor domain of human coagulation factor VII is essential for binding with tissue factor

✍ Bryan J. Clarke; Frederick A. Ofosu; Sampath Sridhara; Robert D. Bona; Frederick 📂 Article 📅 1992 🏛 Elsevier Science 🌐 English ⚖ 580 KB

Epidermal Growth Factor (EGF) in the Hum

Epidermal Growth Factor (EGF) in the Human Placental Infection with Trypanosoma cruzi

✍ S Lin; M.J Sartori; L Mezzano; S.P de Fabro 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 296 KB

Comparison of radioligand assay and immu

Comparison of radioligand assay and immunostaining for epidermal growth factor receptor in human breast cancer

✍ D. J. Hastrich; J. M. Dunn; S. Nicholson; P. Newcomb; Professor J. R. Farndon 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 394 KB 👁 2 views

## Abstract Epidermal growth factor (EGF) receptor status is a useful prognostic indicator in women with breast cancer. Lack of standardization and correlation of methodology for the detection of EGF receptor has hampered its further evaluation. EGF receptor status was ascertained by immunohistoche